Abstract:Background: Many cancers including head and neck squamous cell carcinoma (HNSCC) are characterized by a metabolic rewiring with increased glucose uptake and lactate production, termed as aerobic glycolysis. Targeting aerobic glycolysis presents a promising strategy for cancer therapy. This study investigates the therapeutic potential of glycolysis blockage by targeting phosphofructokinase-2/fructose-2, 6-bisphosphatase 3 (PFKFB3) in HNSCC.Methods: 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) was used as a selective antagonist of PFKFB3. Glycolytic flux was determined by measuring glucose uptake, lactate production and ATP yield. PFKFB3 expression was examined using HNSCC tissue arrays. Cell proliferation, apoptosis and motility were analysed. HNSCC xenograft mouse model and metastasis mouse model were established to examine the therapeutic efficacy of PFK15 in vivo.Results: HNSCC showed an increased PFKFB3 expression compared with adjacent mucosal tissues (P < 0.01). Targeting PFKFB3 via PFK15 significantly reduced the glucose uptake, lactate production and ATP generation in HNSCC cell lines. PFK15 suppressed cell proliferation, halted cell cycle progression and induced cell apoptosis. The invadopodia of HNSCC cells was markedly reduced after PFK15 treatment, thereby impairing cell motility and extracellular matrix degradation ability. The in vivo data from the xenograft mice models proved that PFK15 administration suppressed the tumor growth. And the results from the metastatic mice models showed administration of PFK15 alleviated the lung metastasis of HNSCC and extended the life expectancy of mice.Conclusions: The pharmacological inhibition of PFKFB3 via PFK15 suppressed tumor growth and alleviated metastasis in HNSCC, offering a promising strategy for cancer therapy.

Genomic Deletion of PFKFB3 Decreases In Vivo Tumorigenesis

Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Figure S7 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Figure S3 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Figure S2 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Endothelial PFKFB3 Plays a Critical Role in Angiogenesis.

Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma

Long Noncoding RNA AGPG Regulates PFKFB3-mediated Tumor Glycolytic Reprogramming

The potential utility of PFKFB3 as a therapeutic target

Blockage of Glycolysis by Targeting PFKFB3 Suppresses Tumor Growth and Metastasis in Head and Neck Squamous Cell Carcinoma

Glycolytic Regulatory Enzyme PFKFB3 As a Prognostic and Tumor Microenvironment Biomarker in Human Cancers.

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer

PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer

Inhibition of BUB3 shunts glucose to glycolytic pathway by inducing PFKFB3 accumulation

Non-canonical Roles of PFKFB3 in Regulation of Cell Cycle Through Binding to CDK4.

c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3

Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets

Ras transformation requires metabolic control by 6-phosphofructo-2-kinase

Glucose Metabolism Inhibitor PFK-015 Combined with Immune Checkpoint Inhibitor is an Effective Treatment Regimen in Cancer.